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Establishment of infection of animals with a viral clone will be important for investigating viral determinants of pathogenesis
and monitoring sequence changes in the viral genome in vivo and may find utility as a means of immunization with live-
attenuated virus. To test the efficiency of intramuscular (im) injection of cloned proviral plasmid DNA for establishing feline
immunodeficiency virus (FIV) infection in specific pathogen-free (SPF) cats, groups of cats were inoculated by the im route
with 300, 100, or 30 mg of plasmid DNA containing the infectious molecular clone, FIV-pPPR. A fourth group of cats was
inoculated intradermally with 30 mg of FIV-pPPR plasmid DNA. For comparison, a fifth group received 103 TCID50 of a live
virus stock of FIV-pPPR by intraperitoneal inoculation. Inoculation by im injection with 100 to 300 mg of infectious FIV-pPPR
proviral DNA produced infection detectable by both antiviral antibody and virus isolation from peripheral blood mononuclear
cells. Inoculation by im injection with 30 mg of proviral DNA resulted in infection in two of three inoculated cats. Intradermal
injection with 30 mg of proviral DNA induced infection in one of three cats. Induction of antiviral antibody and viremia was
delayed in cats inoculated with 30 mg compared to cats inoculated with either 100 or 300 mg of proviral DNA. This study
indicates that cloned FIV proviral DNA may replace infectious virion preparations as inocula for pathogenesis and immuniza-
tion studies. q 1997 Academic Press
Intramuscular (im) or intradermal (i.d.) injection of mice ery necessary for establishing a retroviral infection in
with ‘‘naked’’ plasmid DNA expression vectors encoding vivo have been reported (Letvin et al., 1991; Portis et al.,
a specific immunogen results in protein expression and 1992; Willems et al., 1992).
induction of long-lasting cellular and humoral immune For this report, we compared infectivity in cats of feline
responses (Wolff et al., 1990, 1992; Tang et al., 1992; immunodeficiency virus (FIV) cloned proviral DNA with
Ulmer et al., 1993; Raz et al., 1994; Donnelly et al., 1995; virus grown in tissue culture cells. The plasmid encoding
Huygen et al., 1996; Kumar and Sercarz, 1996). Inocula- the PPR molecular clone of FIV (FIV-pPPR) has been
tion of the host with plasmid or bacteriophage l vectors determined infectious by transfection of adherent feline
containing an infectious retroviral DNA genome also pro- cell lines and cocultivation with feline peripheral blood
duces virus expression and infection (Letvin et al., 1991; mononuclear cells (PBMC). Live virus recovered from this
Portis et al., 1992; Willems et al., 1992, 1993). Advantages clone establishes a persistent viremia, detected by virus
of using proviral DNA inoculation over live virus prepara- isolation and seroconversion in cats (Phillips et al.,
tions for both pathogenesis and attenuated viral vaccine 1990; Sparger et al., 1994). Based on data presented
studies include relative stability and ease of standardiza- below, im inoculation of cats with 100 to 300 mg of infec-
tion of plasmid DNA inocula. Sequence changes re- tious FIV-pPPR proviral DNA induced a viremia very simi-
sulting from passage of viral clones in cell culture can lar in kinetics to that observed with a live virus prepara-
be obviated by direct viral DNA injection. In addition, tion of FIV.
plasmid vectors encoding a bacterial ampicillin resis- Supercoiled plasmid DNA for inoculation studies was
tance gene contain short immunostimulatory DNA se- prepared by a standard alkaline lysis protocol and puri-
quences (ISS) which may augment immune responses, fied by centrifugation to equilibrium twice in cesium chlo-
with a T helper cell type 1 (TH1) bias, to viral antigens ride–ethidium bromide gradients (Sambrook et al., 1989).
expressed from the provirus encoded in the plasmid
Plasmid DNA, in concentrations described below, was
(Sato et al., 1996). However, relatively few studies evalu-
resuspended in 1 ml of sterile physiological saline for
ating proviral DNA concentration and mode of DNA deliv-
inoculation by hypodermic syringe (22 gauge) in the rear
limb quadriceps muscle.
The FIV-pPPR virus stock was generated by transfec-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (916) 752-0414. E-mail: eesparger@ucdavis.edu. tion of a feline adherent cell line (Crandell feline kidney
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TABLE 1
Detection of Virus and Antibody against FIV p24 Gag in SPF Cats Inoculated with Molecularly Cloned FIV-pPPR Proviral DNA
Inoculum Virus isolation weeks postinoculation Viral antibody weeks postinoculation
and route/
animal 2 4 8 12 18 2 4 6 8 12 16
300 mg im
479 0 / 0 105 103 0 0 102 102 103 103
521 0 / 0 106 105 0 0 0 102 103 103
522 0 / 0 105 105 0 0 0 0 103 103
100 mg im
337 0 / / 105 105 0 0 0 102 103 103
438 0 / / 105 104 0 0 0 102 103 103
523 0 0 / 105 105 0 0 0 0 103 103
30 mg im
333 0 0 / 105 105 0 0 0 0 102 103
477 0 0 0 0 0 0 0 0 0 0 0
499 0 0 / 0 106 0 0 0 0 102 103
30 mg i.d.
336 0 0 / 0 106 0 0 0 0 102 103
473 0 0 0 0 0 0 0 0 0 0 0
536 0 0 0 0 0 0 0 0 0 0 0
Note. For virus isolations, (/) indicates PBMC (2 1 106) cultures were positive for FIV p24 Gag by day 28 in culture. For time points 12 and 15
weeks p.i., virus isolations were performed on serial dilutions of 106 PBMC and the lowest concentrations of PBMC producing FIV p24 Gag are
noted. Serum antibody titer to FIV p24 Gag was assayed by an ELISA based on recombinant FIV Gag protein [George, 1993, 36] and expressed
as the reciprocal of the highest dilution of serum positive for antibody. Sera with an antibody titer of less than 1:100 are noted as negative (0).
cells) (Sparger et al., 1992) with an infectious FIV-pPPR or live virus, PBMC were isolated from peripheral blood
by density gradient centrifugation in Ficoll/Hypaque (His-provirus construct (pSV-pPPR) encoding a hybrid 5* LTR
composed of the SV40 early enhancer region and TATA topaque; Sigma, St. Louis, MO). PBMC (2 1 106) were
cultured in 6-well plates for 28 days using conditionsbox, a deleted U3 (bp 01 to 010), and full-length R and
U5 (L. Bigornia, H. Louie, and E. E. Sparger, manuscript previously described (Sparger et al., 1994), and cell cul-
ture supernatants were assayed twice a week for viralin preparation). Virus stock was prepared by short-term
passage in feline PBMC. antigen by a capture ELISA for FIV capsid protein p24
(Dandekar et al., 1992). At later time points (12 and 15To determine the minimum dose of FIV-pPPR plasmid
DNA necessary to achieve viral infection by IM inocula- weeks) p.i. with proviral DNA, and all time points p.i.
with live virus preparations, 10-fold serial dilutions of 106tion, groups of specific pathogen-free (SPF) cats were
inoculated with different concentrations of plasmid DNA PBMC were cultured in 24-well plates and monitored for
virus production for 28 days for semiquantitative viruscontaining FIV-pPPR proviral DNA. Juvenile SPF cats (7–
9 months in age) were obtained from the SPF cat colony isolation.
Serum was obtained every 2 weeks from cats in eachof Dr. J. G. Morris and Dr. Q. R. Rogers (University of
California, Davis) and housed in pathogen-free quarters group up to 15–16 weeks postinoculation and titered
for antibody against FIV p24 Gag with an ELISA usingof the Animal Resources Services (University of Califor-
nia, Davis). Group I cats each received a single dose of recombinant FIV p24 (George et al., 1993). Sera found
positive by ELISA at dilutions of 1:100 or greater were300 mg of FIV-pPPR plasmid DNA by im injection; group
II cats received a single im injection of 100 mg of FIV- considered antibody positive and were confirmed by im-
munoblot analysis with whole virus as previously de-pPPR, and group III cats received a single im injection
of 30 mg (Table 1). Each of the group IV cats was inocu- scribed (Yamamoto et al., 1988).
Virus was first detected 4 weeks p.i. in cats inoculatedlated by the i.d. route with 30 mg of FIV-pPPR plasmid
DNA (Table 1). Except for one cat (group II) which dis- with FIV-pPPR plasmid DNA (Table 1), whereas viremia
was detected as early as 2 weeks p.i. in three of fiveplayed a transient fever 3 hr postinoculation (p.i.) no side
effects were observed in cats as a result of either im or cats inoculated with the live virus preparation of FIV-
pPPR (Table 2). Virus was detected by 4 weeks p.i. in alli.d. injection of plasmid proviral DNA. A separate group
of five cats (group V) was inoculated by the ip route with three cats inoculated im with 300 mg FIV-pPPR, in two
of three cats inoculated im with 100 mg, and in four of103 TCID50 of FIV-pPPR virus stock prepared from SPF
feline PBMC (Table 2). five cats inoculated with live virus preparations. By 8
weeks p.i., all three cats injected im with 100 mg and twoTo assess viremia postinjection of either proviral DNA
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TABLE 2
Detection of Virus and Antibody against FIV p24 Gag in SPF Cats Inoculated with FIV-pPPR Virus
Virus isolation weeks postinoculation Viral antibody weeks postinoculation
Animal 2 4 8 12 18 2 4 6 8 12 16
256 — 106 106 106 105 — — — 102 102 102
267 106 105 104 104 104 — — 102 102 103 103
274 — — — — — — — — — — —
293 106 105 106 105 105 — — 102 102 103 103
298 106 106 105 104 105 — — — 102 102 102
Note. For virus isolations, (0) indicates PBMC cultures remained negative for FIV p24 Gag whereas a number value represents the lowest
concentration of cells from which virus could be isolated by day 28 in culture. Serum antibody titer to FIV p24 Gag was assayed by an ELISA based
on recombinant FIV Gag protein [George, 1993, 36] and expressed as the reciprocal of the highest dilution of serum positive for antibody. Sera
with an antibody titer of less than 1:100 are noted as negative (0).
of three cats inoculated im with 30 mg of FIV-pPPR were whereas titers of live retrovirus preparations, determined
by end-point dilution, are not precise. Due to the easeviremic (Table 1). Intradermal inoculation of 30 mg of FIV-
pPPR resulted in viremia (by 8 weeks) in only one of and economy of DNA purification, inoculation of plasmids
encoding infectious proviruses provides an efficientthree cats. Although virus was not detected at 8 weeks
p.i. in cats inoculated with 300 mg of proviral DNA, all mode of delivery of attenuated retrovirus vaccines. DNA
inoculation will facilitate the assessment of immunostim-three of these animals were once again virus positive at
12 and 15 weeks p.i.. ulatory DNA sequences which can be introduced into
the plasmid vector or into the viral genome (Sato et al.,The kinetics of seroconversion and viral antibody titer
were similar for cats inoculated with 300 or 100 mg of 1996). Also from a vaccine standpoint, inoculation of ani-
mals with proviral plasmids is a means to obviate prob-FIV-pPPR plasmid DNA or with the live virus preparation
of FIV-pPPR; viral antibody was detected in these groups lems of stability of live attenuated viruses during in vitro
passage through cell cultures.by 6–8 weeks p.i. (Tables 1 and 2). In contrast, viral
antibody was not detected until 10–12 weeks p.i. in vire-
mic cats inoculated either im or i.d. with 30 mg of FIV- ACKNOWLEDGMENTS
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